Ascrinvacumab
As of the edition of 20 October 2026, Ascrinvacumab is an antibody: stopped in 2014; acts on ACVRL1.
Sources: FDA Orange Book and Purple Book, other approval registers, ClinicalTrials.gov, ChEMBL.
The drug
- Status
- Stopped, 2014
- Kind
- Antibody
- Registered trials
- 9, 1 stopped early
- Disease areas
- Cancer; Digestive system; Bones, joints and muscles; Inherited and neonatal; Lungs and airways; Pregnancy and women's health
US protection
No US approval on record.
With no US approval on record there are no listed US patents or exclusivities.
This is the US only.
Companies that need a new molecule because of this drug
1 company on route A because of this drug.
Companies on route A for this drug
In the product1 company is on route A because of Ascrinvacumab.
See the 1 company on route A for this drug, with the facts behind eachRequest access. Nothing is shown until you do.
Target
| Gene | Protein | UniProt |
|---|---|---|
| ACVRL1 | Activin receptor type-1-like | P37023 |
Registered trials
| Phase | Trials | Completed | Active | Stopped early |
|---|---|---|---|---|
| Phase 1 | 3 | 3 | 0 | 0 |
| Phase 2 | 6 | 3 | 0 | 1 |
| All trials | 9 |
Who ran its trials
| Company | Role | Years |
|---|---|---|
| Pfizer | Lead sponsor of trials | 2007 to now |
| Suzhou Kintor Pharmaceutical | Lead sponsor of trials | 2019 to now |